Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

170.10 USD
+1.81 (+1.08%)
As of Jun 22
chart
Previous Close 168.29
Open 169.80
Volume 158,760
3m Avg Volume 124,222
Today’s High 171.37
Today’s Low 166.93
52 Week High 220.09
52 Week Low 43.34
Shares Outstanding (mil) 3.26
Market Capitalization (mil) 4,400.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
33
FY17
238
FY16
1
FY15
9
EPS (USD)
FY18
-0.156
FY17
-0.183
FY16
-0.274
FY15
-0.139
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
16.21
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
59.72
16.46
LT Debt to Equity (MRQ)
vs sector
59.72
12.19
Return on Investment (TTM)
vs sector
-57.59
14.38
Return on Equity (TTM)
vs sector
-77.45
16.08

EXECUTIVE LEADERSHIP

John Oyler
Chairman of the Board, Chief Executive Officer, Founder, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Wendy Yan
Senior Vice President, Head of Regulatory Affairs, Since 2014
Salary: $68,510.00
Bonus: --
Jason Yang
Senior Vice President, Head of Clinical Development, Since 2014
Salary: $116,129.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Ozannes Corporate Se
94 Solaris Avenue, Camana Bay
GRAND CAYMAN     KY1-1108

Phone: +1345.9494123

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

SPONSORED STORIES